Terms: = Lung cancer AND GATA3, HDR, 2625, ENSG00000107485, MGC5445, MGC5199, MGC2346
293 results:
1. Effective Differences between 2D and 3D Planned Brachytherapy in lung cancer: An Institutional Retrospective Study.
Lalić N; Bojović M; Ivanov O; Ličina J; Popević S; Stjepanović M; Bursać D; Lalić I; Milić R; Tomić S; Parapid B; Anđelković A
Medicina (Kaunas); 2024 Mar; 60(3):. PubMed ID: 38541177
[No Abstract] [Full Text] [Related]
2. NPAS2 dampens chemo-sensitivity of lung adenocarcinoma cells by enhancing DNA damage repair.
Zhang Y; Chen Y; Huang W; Zhou Y; Wang Y; Fu K; Zhuang W
Cell Death Dis; 2024 Jan; 15(1):101. PubMed ID: 38291048
[TBL] [Abstract] [Full Text] [Related]
3. Aggressive prostatic adenocarcinoma with urothelial-like morphology, with frequent CK7/CK20/HMWK expression and occasional diffuse neuroendocrine features: A clinicopathologic study of 12 cases.
Nguyen NJ; Sherman C; van der Kwast TH; Downes MR
Pathol Res Pract; 2024 Feb; 254():155105. PubMed ID: 38218041
[TBL] [Abstract] [Full Text] [Related]
4. Ovarian non-gestational placental site trophoblastic tumor with lung metastasis: further evidence for a distinct category of trophoblastic neoplasm.
Shahi M; Katsakhyan L; Hopkins M; Allen-Rhoades W; Cepress MK; Langstraat C; Ishitani MB; Vang R; Ronnett BM; Xing D
Diagn Pathol; 2024 Jan; 19(1):3. PubMed ID: 38172961
[TBL] [Abstract] [Full Text] [Related]
5. Association of Wiskott-Aldrich syndrome protein (WASp) in epigenetic regulation of B cell differentiation in non-small-cell lung cancer (NSCLC).
Chandnani N; Mandal A; Gupta I; Mukherjee O; Rakshit S; Shanmugam G; George M; Sarkar K
Med Oncol; 2023 Dec; 41(1):28. PubMed ID: 38146020
[TBL] [Abstract] [Full Text] [Related]
6. [TRPS1 expression in salivary gland-type breast carcinoma and its clinical application].
Xu C; Han X; Xu JC; Wang C
Zhonghua Bing Li Xue Za Zhi; 2023 Dec; 52(12):1261-1265. PubMed ID: 38058044
[No Abstract] [Full Text] [Related]
7. Comprehensive analysis of cancer of unknown primary and recommendation of a histological and immunohistochemical diagnostic strategy from China.
Ren M; Cai X; Jia L; Bai Q; Zhu X; Hu X; Wang Q; Luo Z; Zhou X
BMC Cancer; 2023 Dec; 23(1):1175. PubMed ID: 38041048
[TBL] [Abstract] [Full Text] [Related]
8. HepPar1 and GATA-3 Expression in Neuroendocrine Neoplasms: A Potential Trap for Pathologic Diagnosis.
Xu L; Yu G; Jiang L; Song X; Qu G; Luo J; Cai L
Appl Immunohistochem Mol Morphol; 2023 Nov-Dec 01; 31(10):668-672. PubMed ID: 37751245
[TBL] [Abstract] [Full Text] [Related]
9. [Imbalance of lymphoid cells in peripheral blood maintains the immunosuppression and promotes the development of lung adenocarcinoma].
Guo H; Zang L; Yang X; Wu Y; Ma J; Shi W
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2023 Aug; 39(8):729-736. PubMed ID: 37515340
[TBL] [Abstract] [Full Text] [Related]
10. Detecting undetectable - epidemiology, etiology, and diagnosis of carcinoma of unknown primary - systematic review.
Ostojewska J; Wieczorek I; Pachciński O; Zdziennicki W; Burdan F
Folia Med Cracov; 2023 Apr; 63(1):19-37. PubMed ID: 37406274
[TBL] [Abstract] [Full Text] [Related]
11. A two-center experience: The impact of COVID-19 on two brachytherapy programs in Ontario - virtual care, service suspension and radiation therapy workflow.
Chan K; Timotin E; Chung P; Han K; Milosevic M; Schnarr K; Sur R; Bosche J; Harnett N
J Med Imaging Radiat Sci; 2023 Sep; 54(3):436-445. PubMed ID: 37357051
[TBL] [Abstract] [Full Text] [Related]
12. A case report of pulmonary hepatoid adenocarcinoma: promoting standardized diagnosis and treatment of the rare disease.
Xu K; Gao J; Feng L; Fang Y; Tang X
Front Immunol; 2023; 14():1203876. PubMed ID: 37292208
[TBL] [Abstract] [Full Text] [Related]
13. High-dose-rate brachytherapy for airway malignancy a single institution experience.
Siddiqui Z; Falkson C; Hopman W; Mahmud A
Brachytherapy; 2023; 22(4):542-546. PubMed ID: 37217415
[TBL] [Abstract] [Full Text] [Related]
14. Metastases to the kidney from primary lung cancer : clinicopathological analysis of six cases in a single center.
Lian H; Pan X; Hong B; Min J; Huang F
Diagn Pathol; 2023 May; 18(1):60. PubMed ID: 37161448
[TBL] [Abstract] [Full Text] [Related]
15. Risk Factors for Operation Complications of High Dose Rate 3-Dimensional Interstitial Brachytherapy for lung cancer.
Li X; Zhou H; Mou K; Zheng Y; Li H; Ren P; Ye H; Lin S; Pang H; Wu J; Xiang L
Clin Lung Cancer; 2023 Jul; 24(5):e187-e194. PubMed ID: 37149479
[TBL] [Abstract] [Full Text] [Related]
16. A review article on the dosimetry in intraluminal hdr brachytherapy of lung carcinoma.
Kant R; Gupta M; Bisht J; Nautiyal V; Kumar V; Dobhal R; Ahmed M; Saini S
J Cancer Res Ther; 2023 Apr; 19(Supplement):S36-S40. PubMed ID: 37147980
[TBL] [Abstract] [Full Text] [Related]
17. TRPS1 outperforms gata3 in pleural effusions with metastatic breast carcinoma versus mesothelioma.
Baban F; Koepplin JW; Ahmad M; Clarke-Brodber AL; Bois MC; Hartley CP; Sturgis CD
Diagn Cytopathol; 2023 Aug; 51(8):488-492. PubMed ID: 37096814
[TBL] [Abstract] [Full Text] [Related]
18. High dose rate endoluminal brachytherapy in the treatment of endobronchial lesions - experience of a single institution and literature review.
Macías-Lozano MJ; Díaz-Díaz V; Sayago-Gil S; García-Polo C; Jaén-Olasolo J
Support Care Cancer; 2023 Apr; 31(5):260. PubMed ID: 37052737
[TBL] [Abstract] [Full Text] [Related]
19. Clinicopathological Features and Prognosis of Gastrointestinal Metastases From Breast Carcinoma: A Clinicopathological Study of 22 Patients.
Wang S; Li W; Li S; Liu X; Zhang L; Hao C; Meng W; Zhao W; Tong Z
Int J Surg Pathol; 2023 Sep; 31(6):1075-1084. PubMed ID: 36803140
[No Abstract] [Full Text] [Related]
20. gata3 expression in primary lung carcinomas: correlation with histopathologic features and TTF-1, napsin A, and p40 expression.
Wang M; Chen PP; Cai G
Hum Pathol; 2023 May; 135():93-98. PubMed ID: 36702357
[TBL] [Abstract] [Full Text] [Related]
[Next]
